27 research outputs found
Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin A
Immunoglobulin A (IgA) is prominently secreted at mucosal surfaces and coats a fraction of the intestinal microbiota. However, the commensal bacteria bound by IgA are poorly characterized and the type of humoral immunity they elicit remains elusive. We used bacterial flow cytometry coupled with 16S rRNA gene sequencing (IgA-Seq) in murine models of immunodeficiency to identify IgA-bound bacteria and elucidate mechanisms of commensal IgA targeting. We found that residence in the small intestine, rather than bacterial identity, dictated induction of specific IgA. Most commensals elicited strong T-independent (TI) responses that originated from the orphan B1b lineage and from B2 cells, but excluded natural antibacterial B1a specificities. Atypical commensals including segmented filamentous bacteria and Mucispirillum evaded TI responses but elicited T-dependent IgA. These data demonstrate exquisite targeting of distinct commensal bacteria by multiple layers of humoral immunity and reveal a specialized function of the B1b lineage in TI mucosal IgA responses
Costa Rica Rift hole deepened and logged
During Leg 111 of the Ocean Drilling
Program, scientists on the
drilling vessel JOIDES Resolution
studied crustal structure and hydrothermal
processes in the eastern
equatorial Pacific. Leg 111 spent 43
days on its primary objective, deepening
and logging Hole 5048, a deep
reference hole in 5.9-million-year-old
crust 200 km south of the spreading
axis of the Costa Rica Rift. Even before
Leg 111 , Hole 5048 was the deepest
hole drilled into the oceanic crust,
penetrating 274.5 m of sediments and
1,075.5 m of pillow lavas and sheeted
dikes to a total depth of 1,350 m
below sea floor (mbsf). Leg 111 deepened
the hole by 212.3 m to a total
depth of 1,562.3 mbsf (1,287.8 m into
basement), and completed a highly successful suite of geophysical logs
and experiments, including sampling
of borehole waters
On the Regulated Nuclear Transport of Incompletely Spliced mRNAs by HIV-Rev Protein: A Minimal Dynamic Model
A kinetic model for the HIV-1 Rev protein is developed by drawing upon mechanistic information from the literature to formulate a set of differential equations modeling the behavior of Rev and its various associated factors over time. A set of results demonstrates the possibility of oscillations in the concentration of these factors. Finally, the results are analyzed, and future directions are discussed
On the Regulated Nuclear Transport of Incompletely Spliced mRNAs by HIV-Rev Protein: A Minimal Dynamic Model
A kinetic model for the HIV-1 Rev protein is developed by drawing upon mechanistic information from the literature to formulate a set of differential equations modeling the behavior of Rev and its various associated factors over time. A set of results demonstrates the possibility of oscillations in the concentration of these factors. Finally, the results are analyzed, and future directions are discussed
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
BackgroundOncogenes act in a cell-intrinsic way to promote tumorigenesis. Whether oncogenes also have a cell-extrinsic effect on suppressing the immune response to cancer is less well understood.MethodsWe use an in vivo expression screen of known cancer-associated somatic mutations in mouse syngeneic tumor models treated with checkpoint blockade to identify oncogenes that promote immune evasion. We then validated candidates from this screen in vivo and analyzed the tumor immune microenvironment of tumors expressing mutant protein to identify mechanisms of immune evasion.ResultsWe found that expression of a catalytically active mutation in phospho-inositol 3 kinase (PI3K), PIK3CA c.3140A>G (H1047R) confers a selective growth advantage to tumors treated with immunotherapy that is reversed by pharmacological PI3K inhibition. PIK3CA H1047R-expression in tumors decreased the number of CD8+ T cells but increased the number of inhibitory myeloid cells following immunotherapy. Inhibition of myeloid infiltration by pharmacological or genetic modulation of Ccl2 in PIK3CA H1047R tumors restored sensitivity to programmed cell death protein 1 (PD-1) checkpoint blockade.ConclusionsPI3K activation enables tumor immune evasion by promoting an inhibitory myeloid microenvironment. Activating mutations in PI3K may be useful as a biomarker of poor response to immunotherapy. Our data suggest that some oncogenes promote tumorigenesis by enabling tumor cells to avoid clearance by the immune system. Identification of those mechanisms can advance rational combination strategies to increase the efficacy of immunotherapy.</jats:sec
Proceedings of the Ocean Drilling Program:Covering Leg 116 of the cruises of the Drilling Vessel JOIDES Resolution, Colombo, Sri Lanka, to Colombo, Sri Lanka, Sites 717-719, 2 July 1987-19 August 1987 : SR. Vol. 116 Distal Bengal Fan
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) is an aggressive variant of diffuse large B-cell lymphoma (DLBCL) characterized by rare malignant B cells within a robust but ineffective immune cell infiltrate. The mechanistic basis of immune escape in TCRLBCL is poorly defined and not targeted therapeutically. We performed a genetic and quantitative spatial analysis of the PD-1/PD-L1 pathway in a multi-institutional cohort of TCRLBCLs and found that malignant B cells harbored PD-L1/PD-L2 copy gain or amplification in 64% of cases, which was associated with increased PD-L1 expression (P = .0111). By directed and unsupervised spatial analyses of multiparametric cell phenotypic data within the tumor microenvironment, we found that TCRLBCL is characterized by tumor-immune âneighborhoodsâ in which malignant B cells are surrounded by exceptionally high numbers of PD-L1âexpressing TAMs and PD-1+ T cells. Furthermore, unbiased clustering of spatially resolved immune signatures distinguished TCRLBCL from related subtypes of B-cell lymphoma, including classic Hodgkin lymphoma (cHL) and DLBCL-NOS. Finally, we observed clinical responses to PD-1 blockade in 3 of 5 patients with relapsed/refractory TCRLBCL who were enrolled in clinical trials for refractory hematologic malignancies (NCT03316573; NCT01953692), including 2 complete responses and 1 partial response. Taken together, these data implicate PD-1 signaling as an immune escape pathway in TCRLBCL and also support the potential utility of spatially resolved immune signatures to aid the diagnostic classification and immunotherapeutic prioritization of diverse tumor types. Key Points: ⢠Spatially resolved signatures of PD-1/PD-L1 signaling in the tumor microenvironment define T-cell/histiocyte-rich large B-cell lymphoma. ⢠Three of 5 patients with relapsed/refractory TCRLBCL showed objective clinical responses to single-agent PD-1 blockade (pembrolizumab)